Research Article

Frequent Antibiotic Use and Second Breast Cancer Events
Heidi S. Wirtz1, Diana S.M. Buist3,4,5, Julie R. Gralow6, William E. Barlow2,7, Shelly Gray1, Jessica Chubak3,5, Onchee Yu5, Erin J.A. Bowles5, Monica Fujii5, and Denise M. Boudreau1,5

Abstract

Background: Antibiotic use may be associated with higher breast cancer risk and breast cancer mortality, but no study has evaluated the relation between antibiotic use and second breast cancer events (SBCE).

Methods: We conducted a retrospective cohort study among women ≥18 years, diagnosed with incident stage I/II breast cancer during 1990–2008. Antibiotic use and covariates were obtained from health plan administrative databases and medical record review. Frequent antibiotic use was defined as ≥4 antibiotic dispensings in any moving 12-month period after diagnosis. Our outcome was SBCE defined as recurrence or second primary breast cancer. We used multivariable Cox proportional hazards models to estimate HR and 95% confidence intervals (CI), accounting for competing risks.

Results: A total of 4,216 women were followed for a median of 6.7 years. Forty percent were frequent antibiotic users and 558 (13%) had an SBCE. Results are suggestive of a modest increased risk of SBCE (HR, 1.15; 95% CI, 0.88–1.50) among frequent antibiotic users compared with nonusers. Any potential increased risk was not supported when we evaluated recent use and past use. We observed no dose–response trends for SBCE with increasing duration of antibiotic use nor did we find evidence for altered SBCE risk in the antibiotic classes studied.

Conclusions: Frequent antibiotic use may be associated with modestly elevated risk of SBCEs, but the association was not significant.

Impact: Additional investigation by antibiotic class and underlying indication are important next steps given the high prevalence of frequent antibiotic use and growing number of breast cancer survivors. Cancer Epidemiol Biomarkers Prev; 22(9); 1588–99. ©2013 AACR.

Introduction

Each year in the United States more than 200,000 women are diagnosed with breast cancer (1) and currently there are an estimated 2.6 million breast cancer survivors (2). Breast cancer survivors are at risk for recurrence and second primary breast cancers (3).

Antibiotics were proposed as a risk factor for cancer over two decades ago (4). Biologic mechanisms have not been clearly established but suggest antibiotics could have different effects on cancer risk (5). Antibiotics may promote cancer by disrupting the ability of intestinal microflora to metabolize phytochemicals into biologically active compounds hypothesized to protect against cancer (4). Antibiotic-induced disturbance of intestinal microflora may also decrease the risk of some hormonal cancers by disrupting estrogen metabolism, resulting in lower levels of circulating estrogens (5).

Several epidemiologic studies report on antibiotic use and risk of incident breast cancer with conflicting results, as some studies showed no association (6–10) and others have suggested antibiotic use increases risk (11–15). Notably, one of these studies found a dose–response trend for both incident breast cancer risk and breast cancer-related mortality compared with nonusers; as much as a two-fold higher risk of incident breast cancer was found among women with more than 500 cumulative days of antibiotic use (15). To our knowledge, no study to date has evaluated antibiotic use and risk of recurrence and second primary breast cancers among women with a history of breast cancer.

The risk benefit of antibiotic use in relation to breast cancer outcomes is most relevant for chronic or frequent use. Antibiotics are widely prescribed and frequent antibiotic use is common (15) such as for the management of acne and/or rosacea, recurrent urinary tract infections (UTI), or chronic obstructive pulmonary disease (COPD). Antibiotics are often overused or prescribed inappropriately (16); therefore, a better understanding of risks associated with frequent use could bolster measures to improve antibiotic prescribing. We therefore evaluated the association between frequent
antibiotic use and risk of recurrence and second primary breast cancer among women diagnosed with early-stage invasive breast cancer.

Materials and Methods

Study population
This retrospective cohort study was conducted within Group Health Cooperative (GH), a nonprofit integrated health care delivery system that provides comprehensive health care on a prepaid basis to approximately 620,000 individuals throughout Washington State and parts of Idaho. GH is located within the geographic reporting region of the western Washington Cancer Surveillance System, a population-based cancer surveillance, epidemiology, and end results (SEER) registry (2). Women were included if they were: (i) ≥18 years of age; (ii) diagnosed with an incident, histologically confirmed stage I or II (17) breast cancer between January 1, 1990 and December 31, 2008 via the SEER registry; (iii) had no evidence of bilateral disease per the SEER registry; and (iv) enrolled in GH’s integrated group practice for at least 1 year before and 1 year after the breast cancer diagnosis (unless they died). A total of 4,426 subjects were identified and sent to chart review, of which a subset (1,268 women that were not first primaries (44) were excluded for no medical record (n = 72), bilateral disease (n = 6), breast cancers that were not first primaries (n = 79), and no definitive surgery (n = 44)). We required that women be alive and recurrence-free for 120 days after completing definitive surgery for the incident breast cancer, yielding a final cohort of 4,216 women (excluding 5 deaths and 4 metastases before 120 days). The GH Institutional Review Board approved this study.

Data collection
Information on patient and tumor characteristics, breast cancer treatment, outcomes (i.e., recurrence and second primaries), other cancers, comorbid conditions of interest, and breast cancer surveillance were obtained from GH automated databases, review of medical records by trained abstractors, and SEER. Data were collected on all eligible women from 1 year before diagnosis through the earliest of death, disenrollment from GH (a lapse in membership of 90+ days), or end of study (i.e., date of chart abstraction). GH’s automated databases include demographics, enrollment, inpatient and outpatient diagnoses and procedures, breast imaging (e.g., mammography) results, pharmacy dispensings, laboratory results, vital signs, and death (21). Charlson comorbidity index scores (22) were collected annually from medical charts and automated databases. Deaths are determined through GH’s link to Washington State death tapes (23). SEER was the gold standard for incident breast cancer characteristics including year of diagnosis, American Joint Committee on Cancer (AJCC) stage (17), lymph node status, hormone receptor status, and tumor size. Education and menopausal status were collected from a self-administered questionnaire on breast cancer risk factors completed at each screening mammogram (24).

Antibiotic exposure
We identified all outpatient prescription medication use dispensed at any GH pharmacy as well as claims from outside contracting pharmacies. The database contains one record per dispensing that includes: drug name, date of dispensing, quantity dispensed, route, strength, days supply, prescriber, and National Drug Code number. We identified all antibiotics dispensed in the year before each woman’s diagnosis through the end of follow-up.

We included the following antibiotic classes in our exposure ascertainment: penicillins, cephalosporins, sulfonylamides, fluoroquinolones, tetracyclines, nitrofurans, macrolides, ketolides, carbapenems, oxazolidinones (linezolid), glycopeptides (vancomycin), folate antagonists (trimethoprim), nitromidazoles (metronidazole), and methenamine. A dispensing was defined as a prescription with ≤30-day supply. If a dispensing had >30-day supply, we split the dispensing into multiple dispensings reflective of supply ≤30 days. For example, a dispensing of 90-day supply was counted as three 30-day dispensings. On the basis of consensus of a group of prescribers and pharmacists, frequent antibiotic use was defined as having 4+ dispensings for any antibiotic within any moving 12-month period after breast cancer diagnosis. Women were categorized as frequent users at the time of the fourth dispensing. Infrequent antibiotic use was defined as having 1 to 3 antibiotic dispensings within any moving 12-month period. Nonusers were defined as women with no dispensings for an antibiotic. Exposure was time varying. Women were only allowed to transition from nonuser, to infrequent user, to frequent user over time. Once a woman was classified as a frequent user, she remained a frequent user throughout the rest of the follow-up period. We established a priori that frequent antibiotic use was the most clinically meaningful exposure so we only report frequent users versus nonusers in our study. Dispensings before breast cancer diagnosis were not included even though its use could potentially last past diagnosis.

In addition, we evaluated several secondary exposures. To investigate the influence of recency of use on second breast cancer event (SBCE) risk, we stratified frequent use according to the following mutually exclusive categories: nonuse, recent use (became frequent user <3 years before event date), and past use (became frequent user ≥3 years before event date). We restricted this analysis to person-time and events ≥3 years since diagnosis (N = 3,475). We further explored frequent use for each of the 5 most commonly dispensed antibiotic classes where a woman had to fill 4+ prescriptions from the antibiotic class of interest within any moving 12-month period after
diagnosis. Women could contribute to multiple antibiotic classes.

Duration of use was estimated by summing the days supply for each antibiotic prescription to obtain the cumulative days of antibiotic dispensings (15). Duration of use was time varying. We restricted this analysis to women with more than 500 days of follow-up (N = 3,996) to include only those who had the opportunity to be in any of the exposure categories (1–50 days, 51–100 days, 101–500 days and >500 days of antibiotic use). We also estimated duration of use by the top 5 most commonly dispensed antibiotic classes during follow-up. Women could contribute to multiple antibiotic classes if she filled at least one prescription for that class.

Outcome ascertainment

The primary outcome was SBCE, defined as the first ductal carcinoma in situ (DCIS) or an invasive cancer of the ipsilateral (recurrence) or contralateral (second primary) breast or in any regional or distant sites (25). A woman was at risk for a SBCE starting 120 days after completing definitive surgery for the incident breast cancer (index date; ref. 20).

Data analysis

We used multivariable Cox proportional hazards models to estimate HRs and 95% confidence intervals (CI) to assess whether frequent antibiotic use was associated with SBCEs while accounting for competing risks. We also stratified the primary analysis by tumor histology of the incident breast cancer (ductal, lobular, mixed/other). We modeled time from the incident breast cancer with a delayed entry at 120 days postsurgery (19, 20) to the composite and individual outcomes as a function of frequent antibiotic use while adjusting for precision variables (i.e., variables associated with the outcome) and potential confounders. Individual events (i.e., recurrence and second primaries) that make up the composite outcome were also modeled to obtain a comprehensive assessment of the medication effects (26). Women were followed from their index date until the first of SBCE, death, disenrollment, or end of study. In analyses of individual events (e.g., recurrence), women were censored at the earliest of disenrollment, end of follow-up, and other competing events (e.g., death and second primary). We evaluated secondary exposures including frequent antibiotic use by antibiotic class and duration of use (all antibiotics and by antibiotic class). Nonusers were the reference category in all analyses. All exposures were time varying.

All models were adjusted for confounders we selected a priori, including diagnosis year (1990–1994, 1995–1999, 2000–2004, and 2005–2008), age at diagnosis (18–49, 50–59, 60–69, 70–79, and 80+ years), menopausal status at diagnosis (peri- or pre-menopausal, post-menopausal), body mass index (BMI) at diagnosis (<18.5, 18.5–24.9, 25.0–29.9, 30.0–34.9, and 35+ kg/m²), smoking status at diagnosis (current, past, and never/unknown), Charlson comorbidity score (0, 1, 2+, and time-varying), conditions commonly managed with chronic antibiotic use (yes/no, time-varying for acne and/or rosacea, COPD, and UTI), and surveillance mammography receipt in the prior 12 months (yes/no, time-varying). All models were further adjusted for precision variables predictive of SBCEs, including AJCC stage (I, IIA, and IIB) hormone receptor status [estrogen receptor (ER)–/progesterone receptor (PR)–, ER+/PR–, ER+/PR+, and ER+/PR+], primary treatment for the incident breast cancer (mastectomy, breast conserving surgery with radiation, and breast conserving surgery without radiation), and endocrine therapy (yes/no, time-varying).

We evaluated the proportional hazards assumption by testing for an interaction between the exposure variable and the logarithm of time since diagnosis. There was no evidence suggesting a violation of the proportional hazards assumption. All analyses were conducted using SAS statistical software version 9.2 (SAS Institute Inc.).

Sensitivity analyses

We assessed the influence of assumptions about the antibiotic exposure on our results. We varied the definition of frequent antibiotic use to 5+ and 6+ dispensings in any 12-month postdiagnosis period to assess whether frequent antibiotic use was associated with SBCEs while accounting for competing risks. We also excluded women who became frequent antibiotic users during follow-up. During the study period, 1,678 (40%) were frequent antibiotic users with 9,112 person-years of follow-up. Penicillins and cephalosporins were the most commonly prescribed classes and this was consistent throughout the study period. The average time between the first and fourth antibiotic dispensings for frequent users was approximately 6 months and the average cumulative duration of use was 235 days. Characteristics of the study cohort by antibiotic use are described in Table 1. Women who became frequent antibiotic users during follow-up were more likely to have received an antibiotic prescription and to have been frequent antibiotic users in the 12 months prediagnosis compared with nonusers. Frequent antibiotic users were diagnosed in earlier years, had longer duration of follow-up, higher Charlson scores, higher BMI, and were more likely to be older, White, and have acne and/or rosacea, COPD, UTIs, and other cancers.
Table 1. Descriptive characteristics of women, by antibiotic medication use after early-stage breast cancer diagnosis

<table>
<thead>
<tr>
<th>Characteristics at diagnosis of initial breast cancer</th>
<th>Nonuser (n = 525)</th>
<th>Frequent antibiotic user (n = 1,678)</th>
<th>P*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Year of diagnosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1990–1994</td>
<td>87 (16.6)</td>
<td>468 (27.9)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>1995–1999</td>
<td>110 (21.0)</td>
<td>539 (32.1)</td>
<td></td>
</tr>
<tr>
<td>2000–2004</td>
<td>161 (30.7)</td>
<td>427 (25.4)</td>
<td></td>
</tr>
<tr>
<td>2005–2008</td>
<td>167 (31.8)</td>
<td>244 (14.5)</td>
<td></td>
</tr>
<tr>
<td>Years of follow-up</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (IQR)</td>
<td>3.7 (0.5–16.8)</td>
<td>7.6 (0.5–19.2)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Age, y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (IQR)</td>
<td>61 (34–91)</td>
<td>64 (27–93)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>18–39</td>
<td>18 (3.4)</td>
<td>56 (3.3)</td>
<td>0.03</td>
</tr>
<tr>
<td>40–49</td>
<td>94 (17.9)</td>
<td>227 (13.5)</td>
<td></td>
</tr>
<tr>
<td>50–59</td>
<td>131 (25.0)</td>
<td>386 (23.0)</td>
<td></td>
</tr>
<tr>
<td>60–69</td>
<td>122 (23.2)</td>
<td>431 (25.7)</td>
<td></td>
</tr>
<tr>
<td>70–79</td>
<td>93 (17.7)</td>
<td>384 (22.9)</td>
<td></td>
</tr>
<tr>
<td>80+</td>
<td>67 (12.8)</td>
<td>194 (11.6)</td>
<td></td>
</tr>
<tr>
<td>Menopausal status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peri- or Premenopausal</td>
<td>158 (30.1)</td>
<td>442 (26.3)</td>
<td>0.09</td>
</tr>
<tr>
<td>Postmenopausal</td>
<td>367 (69.9)</td>
<td>1,236 (73.7)</td>
<td></td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>436 (83.7)</td>
<td>1,527 (91.2)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>African American</td>
<td>28 (5.4)</td>
<td>39 (2.3)</td>
<td></td>
</tr>
<tr>
<td>American Indian/Alaska Native</td>
<td>8 (1.5)</td>
<td>53 (3.2)</td>
<td></td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>49 (9.4)</td>
<td>55 (3.3)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>4</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Education</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High school or less</td>
<td>51 (21.2)</td>
<td>158 (25.5)</td>
<td>0.18</td>
</tr>
<tr>
<td>At least some college</td>
<td>190 (78.8)</td>
<td>461 (74.5)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>284</td>
<td>1,059</td>
<td></td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;18.5</td>
<td>13 (2.5)</td>
<td>27 (1.6)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>18.5–24.9</td>
<td>209 (40.2)</td>
<td>519 (31.1)</td>
<td></td>
</tr>
<tr>
<td>25.0–29.9</td>
<td>157 (30.2)</td>
<td>546 (32.7)</td>
<td></td>
</tr>
<tr>
<td>30.0–34.9</td>
<td>85 (16.3)</td>
<td>316 (18.9)</td>
<td></td>
</tr>
<tr>
<td>35+</td>
<td>56 (10.8)</td>
<td>261 (15.6)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>5</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>Smoking status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current</td>
<td>33 (6.3)</td>
<td>91 (5.4)</td>
<td>0.10</td>
</tr>
<tr>
<td>Past</td>
<td>51 (9.7)</td>
<td>119 (7.1)</td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>441 (84.0)</td>
<td>1,468 (87.5)</td>
<td></td>
</tr>
<tr>
<td>Charlson score</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>425 (81.0)</td>
<td>1,183 (70.5)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>1</td>
<td>75 (14.3)</td>
<td>363 (21.6)</td>
<td></td>
</tr>
<tr>
<td>2+</td>
<td>25 (4.8)</td>
<td>132 (7.9)</td>
<td></td>
</tr>
<tr>
<td>Medication use in year before diagnosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antibiotic use, ever</td>
<td>132 (25.1)</td>
<td>974 (58.0)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Frequent antibiotic user</td>
<td>8 (1.5)</td>
<td>256 (15.3)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

(Continued on the following page)
Table 1. Descriptive characteristics of women, by antibiotic medication use after early-stage breast cancer diagnosis (Cont’d)

<table>
<thead>
<tr>
<th></th>
<th>Nonuser (n = 525)</th>
<th>Frequent antibiotic user (n = 1,678)</th>
<th>P^a</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AJCC Stage (ref. 17)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>308 (58.7)</td>
<td>1,049 (62.5)</td>
<td>0.06</td>
</tr>
<tr>
<td>IIA</td>
<td>163 (31.0)</td>
<td>433 (25.8)</td>
<td></td>
</tr>
<tr>
<td>IIB</td>
<td>54 (10.3)</td>
<td>196 (11.7)</td>
<td></td>
</tr>
<tr>
<td><strong>Lymph node status</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>363 (78.1)</td>
<td>1,095 (73.9)</td>
<td>0.20</td>
</tr>
<tr>
<td>Positive</td>
<td>102 (21.9)</td>
<td>386 (26.1)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>60</td>
<td>197</td>
<td></td>
</tr>
<tr>
<td><strong>ER/PR status</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ER−/PR−</td>
<td>90 (17.1)</td>
<td>255 (15.2)</td>
<td>0.73</td>
</tr>
<tr>
<td>ER−/PR−</td>
<td>47 (9.0)</td>
<td>167 (10.0)</td>
<td></td>
</tr>
<tr>
<td>ER+/PR−</td>
<td>8 (1.5)</td>
<td>35 (2.1)</td>
<td></td>
</tr>
<tr>
<td>ER+/PR+</td>
<td>350 (66.7)</td>
<td>1,123 (66.9)</td>
<td></td>
</tr>
<tr>
<td>ER and PR unknown</td>
<td>30 (5.7)</td>
<td>98 (5.8)</td>
<td></td>
</tr>
<tr>
<td><strong>Tumor size</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤2 cm</td>
<td>362 (69.0)</td>
<td>1,257 (74.9)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>&gt;2 cm</td>
<td>163 (31.0)</td>
<td>421 (25.1)</td>
<td></td>
</tr>
<tr>
<td><strong>Tumor histology</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ductal</td>
<td>435 (82.9)</td>
<td>1,290 (76.9)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Lobular</td>
<td>31 (5.9)</td>
<td>168 (10.0)</td>
<td></td>
</tr>
<tr>
<td>Mixed/other</td>
<td>59 (11.2)</td>
<td>220 (13.1)</td>
<td></td>
</tr>
<tr>
<td><strong>HER2 Test result</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test done</td>
<td>322 (83.0)</td>
<td>678 (76.1)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Positive/borderline</td>
<td>57 (17.7)</td>
<td>119 (17.6)</td>
<td>0.74</td>
</tr>
<tr>
<td>Negative</td>
<td>263 (81.7)</td>
<td>557 (82.2)</td>
<td></td>
</tr>
<tr>
<td>No result</td>
<td>2 (0.6)</td>
<td>2 (0.3)</td>
<td></td>
</tr>
<tr>
<td><strong>Surgical procedure</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mastectomy ± radiation</td>
<td>176 (33.5)</td>
<td>681 (40.6)</td>
<td>0.001</td>
</tr>
<tr>
<td>BCS + radiation</td>
<td>262 (49.9)</td>
<td>802 (47.8)</td>
<td></td>
</tr>
<tr>
<td>BCS</td>
<td>87 (16.6)</td>
<td>195 (11.6)</td>
<td></td>
</tr>
<tr>
<td><strong>Other treatment</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chemotherapy</td>
<td>164 (31.2)</td>
<td>545 (32.5)</td>
<td>0.59</td>
</tr>
<tr>
<td>Completed course</td>
<td>147 (89.6)</td>
<td>472 (86.6)</td>
<td>0.59</td>
</tr>
<tr>
<td>Endocrine therapy</td>
<td>269 (51.2)</td>
<td>969 (57.7)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td><strong>Characteristics throughout study period</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Comorbidities</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acne and/or rosacea</td>
<td>28 (5.3)</td>
<td>191 (11.4)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>COPD</td>
<td>47 (9.0)</td>
<td>358 (21.3)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>UTI</td>
<td>53 (10.1)</td>
<td>912 (54.4)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Other cancers</td>
<td>22 (4.2)</td>
<td>166 (9.9)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>% Follow-up years with yearly surveillance mammogram</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;50%</td>
<td>146 (27.8)</td>
<td>391 (23.3)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>50%–80%</td>
<td>130 (24.8)</td>
<td>627 (37.4)</td>
<td></td>
</tr>
<tr>
<td>&gt;80%</td>
<td>249 (47.4)</td>
<td>660 (39.3)</td>
<td></td>
</tr>
</tbody>
</table>

**NOTE:** Data are represented as number (%) unless otherwise noted. Frequent antibiotic users included women with 4+ dispensing in any moving 12-month period after diagnosis. Infrequent antibiotic users are not presented here as this is not a clinically meaningful exposure.

Abbreviations: BCS, breast conserving surgery; IQR, interquartile range.

^aTo test for differences of the characteristics between the 2 groups, we used χ² test for categorical variables and Wilcoxon rank-sum test for medians.
compared with nonusers. Frequent antibiotic users were also more likely to initial tumors that were smaller, non-ducal carcinomas tested for HER2 and treated with mastectomy and endocrine therapy. During follow-up, frequent antibiotic users were less likely to receive surveillance mammography compared with nonusers.

Among the 4,216 women in our cohort, 432 (10%) women had a recurrence and 153 (4%) had a second primary breast cancer, a total of 558 having a SBCE (n = 415 recurrences and n = 143 second primary breast cancers). Among recurrences, 67% were distant, 32% were local or regional, and 1% was DCIS. Among second primary cancers, 21% were DCIS, 49% were stage I, 21% were stage II, 4% were stage III/IV, and staging was unavailable for 5%. Histologic types of the SBCEs were 35% ductal, 3% lobular, and 62% mixed/other. The distribution did not differ by exposure status. The median follow-up was 6.7 years and the median time to first SBCE was 3.3 years.

Characteristics of the study cohort by SBCE status are described in Table 2. SBCE cases were diagnosed in earlier years, had shorter duration of follow-up and were more likely to have initial cancers that were not tested for HER2, and were higher stage, larger tumor size, lymph node-positive, and hormone receptor-negative compared with noncases. Consistent with these clinical characteristics, SBCE cases were more likely to receive mastectomy and chemotherapy but less likely to receive endocrine therapy. Women experiencing a SBCE were also more likely to be younger, non-White, pre- or peri-menopausal, less likely to be smokers and less likely to have acne and/or rosacea, COPD, UTIs, and other cancers compared with women who did not experience a SBCE. During follow-up, SBCE cases had shorter duration of antibiotic use and were less likely to be frequent antibiotic users and to receive surveillance mammography.

The unadjusted HRs for frequent use were 1.31 (95% CI, 1.02–1.68) for SBCE, 1.38 (95% CI, 1.03–1.84) for recurrences, and 1.11 (95% CI, 0.67–1.84) for second primaries. HRs from the multivariable-adjusted models suggest a modestly elevated risk of SBCE, including both recurrences and second primaries, with frequent antibiotic use versus no-use but the differences were not statistically significant: 1.15 (95% CI, 0.88–1.50) for SBCE, 1.13 (95% CI, 0.83–1.53) for recurrences, and 1.21 (95% CI, 0.71–2.06) for second primaries (Fig. 1). The potential association with SBCE was not supported when we compared duration of antibiotic use following diagnosis, though CIs included 1.0. Among second primaries, a total of 558 having a SBCE was 3.3 years. The least detectable HRs for SBCEs by frequent antibiotic use versus no-use was 1.20 for increased risk—two-sided test; α = 0.05; β = 0.80. The potential association with SBCE was not supported when we compared duration of antibiotic use with no-use and evaluated dose-response trends. Mechanistic studies suggest antibiotics may alter the risk of cancer primarily through direct effects on intestinal microflora. We hypothesized, therefore, that recency of use would influence the risk of SBCEs, yet we found no differences in risk when stratified by recent use and past use. We did, however, observe differences in the association between frequent antibiotic use and risk of SBCEs by histlogic subtype of the incident breast cancer. Women with ductal and lobular tumors showed elevated risk of SBCEs with frequent antibiotic use and mixed/other tumors showed reduced risk, though CIs were wide and included 1.0.

Although we found no strong evidence of increased risk of SBCEs by antibiotic class, we lacked sufficient power for this secondary aim (least detectable HRs for SBCEs varied by class but all were less than 0.60 for reduced risk and more than 1.50 for increased risk). We observed some statistically significant associations when we examined duration of use by antibiotic class (e.g., sulfonamide use). However, these results should be interpreted cautiously with multiple testing conducted and in the absence of any significant trends.

Because this is the first study on postdiagnosis antibiotic use and SBCEs, we are unable to directly compare our findings with others. A previous study, conducted at GH,
Table 2. Descriptive characteristics of women by SBCE status

<table>
<thead>
<tr>
<th>Characteristics at diagnosis of initial breast cancer</th>
<th>SBCE (N = 4,216)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No (n = 3,658)</td>
<td>Yes (n = 558)</td>
</tr>
<tr>
<td>Year of diagnosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1990–1994</td>
<td>755 (20.6)</td>
<td>195 (34.9)</td>
</tr>
<tr>
<td>1995–1999</td>
<td>1,020 (27.9)</td>
<td>171 (30.6)</td>
</tr>
<tr>
<td>2000–2004</td>
<td>1,073 (29.3)</td>
<td>128 (22.9)</td>
</tr>
<tr>
<td>2005–2008</td>
<td>810 (22.1)</td>
<td>64 (11.5)</td>
</tr>
<tr>
<td>Years of follow-up</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (IQR)</td>
<td>6.7 (0.4–19.4)</td>
<td>3.3 (0.5–16.5)</td>
</tr>
<tr>
<td>Age, y</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (IQR)</td>
<td>63 (28–95)</td>
<td>62 (29–89)</td>
</tr>
<tr>
<td>18–39</td>
<td>112 (3.1)</td>
<td>27 (4.8)</td>
</tr>
<tr>
<td>40–49</td>
<td>544 (14.9)</td>
<td>102 (18.3)</td>
</tr>
<tr>
<td>50–59</td>
<td>866 (23.7)</td>
<td>129 (23.1)</td>
</tr>
<tr>
<td>60–69</td>
<td>889 (24.3)</td>
<td>129 (23.1)</td>
</tr>
<tr>
<td>70–79</td>
<td>824 (22.5)</td>
<td>116 (20.8)</td>
</tr>
<tr>
<td>80+</td>
<td>423 (11.6)</td>
<td>55 (9.9)</td>
</tr>
<tr>
<td>Menopausal status</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peri- or Premenopausal</td>
<td>956 (26.1)</td>
<td>189 (33.9)</td>
</tr>
<tr>
<td>Postmenopausal</td>
<td>2,702 (73.9)</td>
<td>369 (66.1)</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>3,232 (88.7)</td>
<td>487 (87.3)</td>
</tr>
<tr>
<td>African American</td>
<td>104 (2.9)</td>
<td>32 (5.7)</td>
</tr>
<tr>
<td>American Indian/Alaska Native</td>
<td>104 (2.9)</td>
<td>9 (1.6)</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>203 (5.6)</td>
<td>30 (5.4)</td>
</tr>
<tr>
<td>Unknown</td>
<td>15</td>
<td>0</td>
</tr>
<tr>
<td>Education</td>
<td></td>
<td></td>
</tr>
<tr>
<td>High school or less</td>
<td>393 (23.5)</td>
<td>25 (21.4)</td>
</tr>
<tr>
<td>At least some college</td>
<td>1,279 (76.5)</td>
<td>92 (78.6)</td>
</tr>
<tr>
<td>Unknown</td>
<td>1,986</td>
<td>441</td>
</tr>
<tr>
<td>BMI (kg/m&lt;sup&gt;2&lt;/sup&gt;)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;18.5</td>
<td>55 (1.5)</td>
<td>14 (2.5)</td>
</tr>
<tr>
<td>18.5–24.9</td>
<td>1,269 (34.8)</td>
<td>184 (33.3)</td>
</tr>
<tr>
<td>25.0–29.9</td>
<td>1,186 (32.6)</td>
<td>176 (31.8)</td>
</tr>
<tr>
<td>30.0–34.9</td>
<td>666 (18.3)</td>
<td>100 (18.1)</td>
</tr>
<tr>
<td>35&lt;sup&gt;+&lt;/sup&gt;</td>
<td>467 (12.8)</td>
<td>79 (14.3)</td>
</tr>
<tr>
<td>Unknown</td>
<td>15</td>
<td>5</td>
</tr>
<tr>
<td>Smoking status</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current</td>
<td>230 (6.3)</td>
<td>23 (4.1)</td>
</tr>
<tr>
<td>Past</td>
<td>318 (8.7)</td>
<td>34 (6.1)</td>
</tr>
<tr>
<td>Never</td>
<td>3,110 (85.0)</td>
<td>501 (89.8)</td>
</tr>
<tr>
<td>Charlson score</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>2,784 (76.1)</td>
<td>445 (79.7)</td>
</tr>
<tr>
<td>1</td>
<td>625 (17.1)</td>
<td>79 (14.2)</td>
</tr>
<tr>
<td>2&lt;sup&gt;+&lt;/sup&gt;</td>
<td>249 (6.8)</td>
<td>34 (6.1)</td>
</tr>
<tr>
<td>Medication use in year before diagnosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antibiotic use, ever</td>
<td>1,621 (44.3)</td>
<td>251 (45.0)</td>
</tr>
<tr>
<td>Frequent antibiotic user</td>
<td>277 (7.6)</td>
<td>45 (8.1)</td>
</tr>
<tr>
<td>AJCC stage (ref. 17)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>2,384 (65.2)</td>
<td>264 (47.3)</td>
</tr>
<tr>
<td>II&lt;sup&gt;A&lt;/sup&gt;</td>
<td>906 (24.8)</td>
<td>172 (30.8)</td>
</tr>
<tr>
<td>IIB</td>
<td>368 (10.1)</td>
<td>122 (21.9)</td>
</tr>
</tbody>
</table>

(Continued on the following page)
Table 2. Descriptive characteristics of women by SBCE status (Cont’d)

| SBCE (N = 4,216) | 
|------------------|------------------|
|                  | No (n = 3,658)   | Yes (n = 558)   | P<sup>a</sup> |
| Lymph node status|                  |                  |              |
| Negative         | 2,525 (77.4)     | 322 (64.3)       | <0.001       |
| Positive         | 739 (22.6)       | 179 (35.7)       |              |
| Unknown          | 394              | 57              |              |
| ER/PR Status     |                  |                  |              |
| ER−/PR−          | 531 (14.5)       | 136 (24.4)       | <0.001       |
| ER+/PR−          | 319 (8.7)        | 64 (11.5)        |              |
| ER−/PR+          | 47 (1.3)         | 14 (2.5)         |              |
| ER+ PR−          | 2,572 (70.3)     | 316 (56.6)       |              |
| ER and PR unknown| 189 (5.2)        | 28 (5.0)         |              |
| Tumor size       |                  |                  |              |
| <2 cm            | 2,785 (76.1)     | 325 (58.5)       | <0.001       |
| >2 cm            | 873 (23.9)       | 231 (41.5)       |              |
| Unknown          | 0                | 2               |              |
| HER2 Test result |                  |                  |              |
| Test done        | 1,874 (80.5)     | 200 (73.0)       | <0.01        |
| Positive/borderline | 311 (16.6)      | 42 (21.0)        | 0.21         |
| Negative         | 1,556 (83.0)     | 158 (79.0)       |              |
| No result        | 7 (0.4)          | 0               |              |
| Surgical procedure|                |                  |              |
| Mastectomy ± radiation | 1,289 (35.2)  | 232 (41.6)       | <0.001       |
| BCS ± radiation  | 1,927 (52.7)     | 245 (43.9)       |              |
| BCS              | 442 (12.1)       | 81 (14.5)        |              |
| Other treatment  |                  |                  |              |
| Chemotherapy     | 1,142 (31.2)     | 234 (41.9)       | <0.001       |
| Completed course | 1,003 (87.8)     | 209 (89.3)       | 0.74         |
| Endocrine therapy| 2,101 (57.4)     | 262 (47.0)       | <0.001       |
| Characteristics throughout study period | | | |
| Comorbidities    |                  |                  |              |
| Acne and/ or rosacea | 329 (9.0)       | 31 (5.6)         | <0.01        |
| COPD             | 574 (15.7)       | 58 (10.4)        | <0.001       |
| UTI              | 1,392 (38.1)     | 146 (26.2)       | <0.001       |
| Other cancers    | 303 (8.3)        | 24 (4.3)         | <0.001       |
| Antibiotic use postdiagnosis |       |                  |              |
| Frequent user    | 1,476 (40.3)     | 202 (36.2)       | <0.001       |
| Infrequent user  | 1,762 (48.2)     | 251 (45.0)       |              |
| Nonuser          | 420 (11.5)       | 105 (18.8)       |              |
| Max cumulative days supply | |                  |              |
| 0                | 420 (11.5)       | 105 (18.8)       | <0.001       |
| 1–50             | 1,527 (41.7)     | 250 (44.8)       |              |
| 51–100           | 723 (19.8)       | 89 (15.9)        |              |
| 101–500          | 838 (22.9)       | 104 (18.6)       |              |
| >501             | 150 (4.1)        | 10 (1.8)         |              |
| % of Follow-up years with yearly surveillance mammogram | | | |
| <50%             | 793 (21.7)       | 146 (26.2)       | <0.01        |
| 50%–80%          | 1,284 (35.1)     | 155 (27.8)       |              |
| >80%             | 1,581 (43.2)     | 257 (46.1)       |              |

NOTE: Data are represented as number (%) unless otherwise noted. Frequent antibiotic users included women with 4+ dispensing in any moving 12-month period after diagnosis. Infrequent antibiotic users included women with 1 to 3 dispensing in any moving 12-month period after diagnosis.

Abbreviations: BCS, breast conserving surgery; IQR, interquartile range.

*To test for differences of the characteristics between the 2 groups, we used χ² test for categorical variables and Wilcoxon rank-sum test for medians.
evaluated prediagnosis antibiotic use relative to incident breast cancer (15). In that case–control study of 2,266 women diagnosed in 1993–2001, prediagnosis antibiotic use was associated with higher risk of incident breast cancer compared with nonusers and the association was stronger with increased duration of use. ORs (95% CIs) for breast cancer were 1.45 (1.24–1.69) for 1–50 days use, 1.53 (1.28–1.83) for 51–100 days use, 1.68 (1.42–2.00) for 101–500 days use, 2.14 (1.60–2.88) for 501–1,000 days use, and 2.07 (1.48–2.89) for 1,001-day use (15). Although our findings among GH enrollees also suggest a higher risk of SBCEs, the magnitude of association is lower in our study, had wide CIs and showed no trend with increasing duration of use. The inconsistent results may be attributed to different exposures as Velicer and colleagues only evaluated antibiotic use preincident breast cancer diagnosis (15). We also evaluated different outcomes. As such, the risk of second primary breast cancers in our study is most comparable with the outcome of incident breast cancer in Velicer and colleagues. Our findings suggest frequent antibiotic use after diagnosis may increase risk of second breast primaries but CIs included 1.0. Our study was powered to evaluate the development of new cancers and we only observed 143 second breast primaries (least detectable HRs for second primaries by frequent antibiotic use vs. no-use was 0.58 for reduced risk and 1.55 for increased risk).

We developed the definition of frequent antibiotic use de novo based on clinician input and coupled this with sensitivity analyses where different thresholds for frequent antibiotic use provided consistent results with the primary analysis. Compared with nonusers, frequent antibiotic users were diagnosed in earlier years and had longer duration of follow-up, which gives more opportunity to observe a SBCE. Prediagnosis antibiotic exposure may confound the association between postdiagnosis frequent antibiotic use and risk of SBCEs. Including frequent antibiotic use during the 12 months prediagnosis did not change our results but it is possible that this was not a sufficient duration of prediagnosis exposure. Subjects were from a single health plan, which may not represent other care settings or populations. However, being enrolled in a health plan mitigates disparities in care that may exist among women without health coverage. There is always the potential for exposure misclassification for patients who receive a dispensing, but fail to take the drug. We required multiple dispensings in a year in order for a woman to be classified as a frequent user, which minimizes exposure misclassification as multiple dispensings in a defined period of time increase the possibility that women actually took the medication. Women who received medications at non-GH pharmacies without submitting a claim to GH may be erroneously classified as nonusers. This is likely minor as previous studies have found GH enrollees obtained 97% of their medications at GH owned or contracting pharmacies (27, 28). Residual confounding from unknown factors we did not adjust for and from known factors we did adjust for (e.g., diagnosis year, Charlson score, BMI) is always possible. Of importance, we adjusted for conditions associated with chronic antibiotic use. Other studies found no association between UTIs and breast cancer risk (13) and no differences in breast cancer risk comparing different indications for antibiotic use (15). We also
found no association between any of the comorbidities of interest and SBCE.

Major strengths of our study include: a large sample of population-based breast cancer cases with extensive follow-up; complete ascertainment of incident cancer cases and tumor characteristics through a validated registry; detailed information on incident breast cancer characteristics and treatment; availability of medical charts to identify recurrences and details on recurrent cancer characteristics; unbiased information on medications dispensed; detailed information on comorbidities and mammographic exams that enabled us to examine confounding in a robust manner; and application of robust analytic methods to address potential competing risks and informative censoring.

Although not statistically significant, our study provides a weak signal that frequent antibiotic use may be associated with a modestly elevated risk of SBCEs among women with a history of early-stage invasive breast cancer. This study is an important part of ongoing efforts to improve cancer prognosis and address drug safety. Given the public health importance of learning more about survivorship care and factors that influence breast cancer prognosis, further investigation into this

<table>
<thead>
<tr>
<th>Antibiotic exposure</th>
<th>SBCE (n cases = 558)</th>
<th>Recurrence (n cases = 415)</th>
<th>Second primary breast cancer (n cases = 143)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any antibiotic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1–50 days</td>
<td>0.82 (0.63–1.08)</td>
<td>0.79 (0.58–1.07)</td>
<td>0.94 (0.52–1.71)</td>
</tr>
<tr>
<td>51–100 days</td>
<td>0.98 (0.71–1.37)</td>
<td>0.82 (0.56–1.20)</td>
<td>1.56 (0.81–3.02)</td>
</tr>
<tr>
<td>101–500 days</td>
<td>1.14 (0.81–1.61)</td>
<td>1.11 (0.75–1.65)</td>
<td>1.37 (0.68–2.76)</td>
</tr>
<tr>
<td>≥501 days</td>
<td>0.83 (0.42–1.66)</td>
<td>0.96 (0.44–2.08)</td>
<td>0.59 (0.13–2.71)</td>
</tr>
<tr>
<td></td>
<td>0.25</td>
<td>0.41</td>
<td>0.33</td>
</tr>
<tr>
<td>Penicillin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1–50 days</td>
<td>1.25 (1.04–1.50)</td>
<td>1.23 (1.00–1.53)</td>
<td>1.28 (0.89–1.84)</td>
</tr>
<tr>
<td>51–100 days</td>
<td>1.14 (0.74–1.76)</td>
<td>1.06 (0.61–1.83)</td>
<td>1.37 (0.65–2.85)</td>
</tr>
<tr>
<td>≥101 days</td>
<td>1.22 (0.71–2.11)</td>
<td>1.19 (0.61–2.33)</td>
<td>1.31 (0.50–3.44)</td>
</tr>
<tr>
<td></td>
<td>0.07</td>
<td>0.16</td>
<td>0.22</td>
</tr>
<tr>
<td>Cephalosporin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1–50 days</td>
<td>1.20 (1.00–1.44)</td>
<td>1.13 (0.92–1.40)</td>
<td>1.39 (0.97–2.01)</td>
</tr>
<tr>
<td>51–100 days</td>
<td>1.12 (0.73–1.72)</td>
<td>1.00 (0.59–1.69)</td>
<td>1.48 (0.70–3.15)</td>
</tr>
<tr>
<td>≥101 days</td>
<td>1.18 (0.65–2.14)</td>
<td>1.13 (0.55–2.32)</td>
<td>1.52 (0.52–4.50)</td>
</tr>
<tr>
<td></td>
<td>0.13</td>
<td>0.42</td>
<td>0.10</td>
</tr>
<tr>
<td>Sulfonamide</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1–50 days</td>
<td>0.90 (0.73–1.11)</td>
<td>0.99 (0.78–1.25)</td>
<td>0.71 (0.47–1.07)</td>
</tr>
<tr>
<td>51–100 days</td>
<td>0.74 (0.43–1.27)</td>
<td>1.08 (0.62–1.90)</td>
<td>0.12 (0.02–0.91)</td>
</tr>
<tr>
<td>≥101 days</td>
<td>1.14 (0.55–2.36)</td>
<td>1.20 (0.48–2.98)</td>
<td>1.11 (0.33–3.69)</td>
</tr>
<tr>
<td></td>
<td>0.35</td>
<td>0.82</td>
<td>0.04</td>
</tr>
<tr>
<td>Fluoroquinolone</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1–50 days</td>
<td>1.03 (0.82–1.29)</td>
<td>1.13 (0.87–1.46)</td>
<td>0.70 (0.43–1.13)</td>
</tr>
<tr>
<td>51–100 days</td>
<td>1.09 (0.56–2.10)</td>
<td>1.32 (0.63–2.75)</td>
<td>0.65 (0.15–2.79)</td>
</tr>
<tr>
<td>≥101 days</td>
<td>1.79 (0.77–4.15)</td>
<td>2.12 (0.84–5.34)</td>
<td>1.02 (0.13–7.72)</td>
</tr>
<tr>
<td></td>
<td>0.40</td>
<td>0.17</td>
<td>0.21</td>
</tr>
<tr>
<td>Tetracycline</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1–50 days</td>
<td>0.88 (0.68–1.14)</td>
<td>0.73 (0.52–1.00)</td>
<td>1.40 (0.90–2.16)</td>
</tr>
<tr>
<td>51–100 days</td>
<td>0.92 (0.43–1.96)</td>
<td>0.73 (0.27–2.00)</td>
<td>1.69 (0.51–5.56)</td>
</tr>
<tr>
<td>≥101 days</td>
<td>0.90 (0.45–1.79)</td>
<td>0.93 (0.40–2.14)</td>
<td>0.85 (0.26–2.86)</td>
</tr>
<tr>
<td></td>
<td>0.42</td>
<td>0.14</td>
<td>0.41</td>
</tr>
</tbody>
</table>

NOTE: Duration of antibiotic use is defined as cumulative days of dispensing. Nonusers were the reference category for all analyses. A woman could contribute to multiple antibiotic classes if she filled at least one prescription for that class. We excluded 20 women from analyses due to missing BMI information.

*All models adjusted for age, incident breast cancer diagnosis year, AJCC stage, hormone receptor status, primary treatment for the initial breast cancer, endocrine therapy, BMI, smoking status, menopausal status, Charlson comorbidity score, acne and/or rosacea, COPD, UTI, and receipt of surveillance mammography.
common exposure among women with a history of breast cancer is warranted. As our findings provide only an initial signal, additional studies to better understand the role of frequent antibiotic use and SBCEs would be helpful. Furthermore, evaluations in different study populations and investigation of frequent use by antibiotic class and underlying indication would also be a next step in understanding such an association. This would allow breast cancer survivors and their providers to make more informed decisions about antibiotic selection for managing medical conditions where frequent use is necessary.

**Disclosure of Potential Conflicts of Interest**

Heidi S. Wirtz has ownership interest (including patents) in Teva Pharmaceuticals. No potential conflicts of interest were disclosed by the other authors.

**Authors’ Contributions**

Conception and design: H.S. Wirtz, D.S.M. Buist, J.R. Gralow, E.J.A. Bowles, D.M. Boudreau


Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): D.S.M. Buist, J. Chubak, M. Fuji, D.M. Boudreau


Writing, review, and/or revision of the manuscript: H.S. Wirtz, D.S.M. Buist, J.R. Gralow, W.E. Barlow, S. Gray, J. Chubak, O. Yu, E.J.A. Bowles, D.M. Boudreau

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): H.S. Wirtz, D.M. Boudreau

Study supervision: H.S. Wirtz, D.S.M. Buist, M. Fuji, D.M. Boudreau

**Grant Support**

The work was supported by a grant from the National Cancer Institute (CA120562, Principal Investigator: to D.M. Boudreau). Part of the data collection was supported by a grant from the National Cancer Institute (U01CA63731, to D.S.M. Buist). The collection of cancer incidence data used in this study was supported by the Cancer Surveillance System of the Fred Hutchinson Cancer Research Center, which is funded by contract No. N01-CN-67009 and N01-PC-55142 from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute with additional support from the Fred Hutchinson Cancer Research Center and the State of Washington.

The costs of publication of this article were defrayed in part by the Payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received May 1, 2013; revised June 21, 2013; accepted June 24, 2013; published OnlineFirst July 5, 2013.

**References**


